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A double-blind crossover trial of fenoprofen calcium
versus acetylsalicylic acid (aspirin) and placebo in 10
outpatients with active rheumatoid arthritis, is reported.
Both fenoprofen and aspirin were found to be similarly
effective agents in rheumatoid arthritis with an average
daily dose of 2,1 g fenoprofen compared with 4,5 g
aspirin.
No significant changes in selected laboratory tests were
observed with either drug. The patients reported twice
as many side-effects with aspirin; in fact, no drug-related
side-effects could be attributed to fenoprofen itself. It
is concluded that fenoprofen is a valuable and safe
addition to the rheumatologist's armamentarium.
s. Air. Med. J., 48, 899 (1974).
The cause of and specific therapy for rheumatoid arthritis
(RA) remain unknown. Antirheumatic agents are gauged
to be potent when they exhibit anti-inflammatory and
analgesic properties. The ideal agent should, in addition,
have a wide margin of safety and a minimum of side-
effects.
Fenopron (fenoprofen) is dl-2-(3-phenoxyphenyl) pro-
pionic acid, a non-steroidal compound with anti-inflam-
matory, antipyretic and analgesic properties in experi-
mental animals' and in man.'·< Fenoprofen calcium is the
calcium salt of the same moiety. Fenoprofen calcium and
sodium share the same bio-availability, distribution and
elimination in man," with the calcium salt having as an
advantage its lack of hygroscopic activity.
The drug is rapidly and efficiently absorbed from the
gastro-intestinal tract, is tightly bound to serum albumin
and has a half-life of about 160 minutes. Over 90% of
the dose is metabolised, presumably by the liver; the
plasma is cleared rapidly of metabolites by the kidneys.
Absorption is unaffected by the administration of antacids.
The mode of action, as with other antirheumatics, remains
hypothetical.' The critical evaluation of antirheumatic
agents remains fraught with difficulty. The prime aim
must be to identify and measure reversible features of
the disease.! Lee et al." have reviewed the subject in detail
and stress the need for sound experimental design based
upon the selection of relevant assessment indices.
PATIENTS AND METHODS
A stage 3 double-blind crossover trial of fenoprofen
versus aspirin and placebo in 10 outpatients over a 9-
week period was carried out.
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Patients
Informed consent was obtained from the patients: 4
males and 6 females. The ages ranged from 26 to 69
years. All had been under the investigator's care for more
than 6 months, and exhibited active rheumatoid arthritis
in a steady state. Active disease is defined as exceeding
the limits stated in at least 3 of the following 6 parameters:
more than 6 joints painful or tender on motion; more than
3 joints swollen; more than three-quarters of an hour
duration of morning stiffnes:;; grip strength (sphygmo-
manometer cuff in mmHg); with male: less than 192, and
female: less than 146; 15 m walking time more than
11,5 secs; and Westergren ESR more than 28 mm/hr.
For the purposes of the study, steady state is defined as a
2-week period of time during which there is no change,
or relatively little, occurring in the patient's clinical status.
Using criteria elaborated by the American Rheumatism
Association' the patients were classified as probable,
definite or classical RA. Furthermore 4 classes of functional
capacity (class I complete function to class IV largely
incapacitated, permitting little or no self-care), and 4
anatomical stages (based on radiological experiences) were
used for categorising the subjects.
The outpatients' study is carried out under conditions
which are much more relevant to the patients' day-to-day
life. However, there is the problem of failure to take the
prescribed drugs.'· Daily and weekly tablet consumption,
and count of residual drugs, were used to ascertain this.
Design of Study
The test medications were administered as identically
appearing capsules of fenoprofen 200 mg and aspirin
(ASA, Lilly) 500 mg, in such a way that each patient
began with one week of placebo, followed by 3 weeks'
therapy with either fenoprofen or aspirin, then one week
placebo followed by 3 weeks' therapy with the alternate
active medication, and then a final week of placebo.
Each patient accrued 3 therapy weeks each for placebo,
fenoprofen and aspirin, i.e. 9 weeks of observation. The
actual order of medication was determined at random.
During placebo periods, patients were permitted addi-
tional aspirin 325-mg tablets ad lib. During the weeks
of active study medication, patients were permitted addi-
tional medication in the form of propoxyphene napsylate
100-mg tablets when needed, but not exceeding 4/day.
Dosage was fixed at intervals of every 6 hours; the
patients setting an alarm clock to awake for the midnight
dose if necessary. The dose level was a sliding one, when
active medication was taken at 1 capsule q.i.d. and could
be increased gradually in the event of poor or inadequate
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response to 3 capsules every 6 hours. The value of a
variable dose lies in obviating dose-dependent negative or
positive trial results."
Assessment Indices
There is no single measurement which reflects the
rheumatoid status. A number of criteria are therefore
used in producing composite indices." While all these
have proved valuable in the assessment of efficacy of new
compounds, none has proved superior to simple demon-
stration of pain relief."
The following parameters were used to determine the
effectiveness of medication:
Subjective evaluations were classified as follows:
1. Observer's evaluation of effect of medication since
last visit (a weekly event). Scoring: very good = 1; good
= 2; fair = 3; poor = 4; very poor = 5.
2. Patient's evaluation of medication since last visit.
A weekly follow-up with the same scoring as 1.
3. Comfort index based on the patient's rating of his
well-being regarding his arthritic pain. A daily telephonic
interview, 'How do you feel today?', expressed as a weekly
score: very good = 7; good = 14; fair = 21; poor = 28;
very poor = 35.
4. The severity of morning stiffness ascertained every
day and expressed as: none = 0; a little = 7; some = 14;
a lot = 21; terrible = 28.
5. Finally the daily duration in hours of morning
stiffness totalled in hours per week.
Objective evaluations were the following:
1. At the weekly follow-up, joint involvement was rated
along the lines of Lansbury's articular index." The number
of joints involved is based upon the three features:
limitation of motion, tenderness with pressure or move-
ment and swelling. The total number of swollen joints was
noted separately.
2. Grip strength. This is determined weekly by means
of a sphygmomanometer cuff inflated to 20 mmHg. The
average of 3 readings for each hand is expressed as the
sum of the grip strengths for both hands.
3. Walking times were measured with a stop-watch
as the number of seconds required for the patients to
walk 15 m.
Over-all, each patient was contacted at approximately
the same time each morning by telephone and questioned
concerning the comfort index, morning stiffness and· the
number of aspirin or propoxyphene tablets taken in
addition to the test. medication. They were further ques-
tioned about any adverse effects experienced the previous
day. General questions were placed first and were followed
by leading questions about specific side-effects cited in
the same order each day."
At the weekly follow-up, the articular index, grip
strength and walking tIme were recorded. The number of
test tablets and/or aspirin and propoxyphene returned were
counted to check patient intake. At the weekly visit.
selected laboratory results to monitor safety were per-
formed, which included full blood count, platelet counts,
Westergren sedimentation rates and routine urine-analysis.
Blood-urea nitrogen (BUN), alkaline phosphatase, lactic
dehydrogenase and SGOT results were recorded 5 times
during the study: after first placebo week (week 1); after
3 weeks of active therapy and on the first half of the
crossover (week 4); after the middle study placebo week
(week 5); after 3 weeks of active medication on the last
half of the crossover (week 8); and after the final placebo
week. The stool was tested for occult blood twice. a week.
RESULTS
The trial design provided an in-depth study of 10 patients,
all of whom completed the trial. The data accumulated are
cop.ious and for the purposes of clarity and brevity 16
vanables have been divided for statistical analysis into
two sections--efficacy and laboratory. Table I contains
the average response for each efficacy variable on the
last week of active therapy and during the preceding
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TABLE 11. FREQUENCIES WITH WHICH ACTIVE THERAPIES DIFFERED FROM EACH OTHER
gal
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Placebo week Third week of Placebo week
preceding fenoprofen fenoprofen preceding aspirin Third v.eek of
Variable Normal therapy therapy therapy aspirin therapy
BUN 7-20 mg/100 ml 15,5 18,7 15,3 21,4
Alkaline phosphatase 9-35 IU 29,3 28,0 28,9 27,3
LDH 40-100 142,1 136,1 132,4 130,4
SGOT <28 20,7 19,5 16,8 23,8
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Table II presents the frequencies with which the active
therapies differed from each other and their corresponding
preceding placebo weeks. In this Table, a P = 0,10
cutoff has been used rather than the more conventional
0,05 because of the small number of subjects. A simple
binomial test was applied pairwise to discriminate among
the treatments. Comparisons with placebo are single-tailed
tests; those between fenoprofen and aspirin are two-tailed.
The conclusions which were made as a result of these
tests are presented in this table.
Tables III and IV are the laboratory analogues to
Tables I and n. They are identical with the efficacy tables,
with the exception that all tests have two-sided alternatives.
Efficacy Factors
Examination of Tables I and II indicates the similarity
between fenoprofen and aspirin at the doses used in this
study. In fact, no differences were observed between
fenoprofen and aspirin which could not be readily assigned
to random variation. Both fenoprofen and aspirin were
superior to placebo for most of the efficacy parameters.
The number of ad lib. aspirin taken during the preceding
placebo week was comparable for the fenoprofen and
aspirin regimens. Propoxyphene consumption was irregular
and does not indicate a substantial difference between
the regimens.
TABLE IV. FREQUENCIES WITH WHICH ACTIVE THERAPIES
DIFFERED FROM EACH OTHER IN LABORATORY VALUES
Ties + P
BUN
Placebo-fenoprofen 0 1 9 0,05
Placebo-aspirin 0 3 7 NS
Fenoprofen-aspirin 0 4 6 NS
Alkaline phosphatase
Placebo-fenoprofen 1 6 3 NS
Placebo-aspirin 0 7 3 NS
Fenoprofen-aspirin 0 6 4 NS
LDH
P!acebo-fenoprofen 0 5 5 NS
Placebo-aspirin 0 5 5 NS
Fenoprofen-aspirin 0 5 5 NS
SGOT
Placebo-fenoprofen 2 2 6 NS
Placebo-aspirin 1 2 7 NS
Fenoprofen-aspirin 1 4 5 NS
Laboratory Values
Laboratory values were essentially the same during
placebo, aspirin and fenoprofen periods, with one excep-
tion. There was an apparent increase in blood-urea nitrogen
during the active therapy periods as compared with
TABLE V. FINAL EVALUATION: COMPARISON OF ASPIRIN AND FENOPROFEN (FPN)
Comparison with Medication dose
Efficacy Side-effects previous therapy acceptability
Aspirin None Patients better during both Both well
better periods of study than with tolerated
steroids
FPN None Better with FPN than when Both well
better on indomethacin tolerated
FPN None Better during both periods Both well
better as compared with previous tolerated
indomethacin
Equal Present with Both study periods were FPN better
aspirin only better than any previous tolerated
therapy
Equal None Both study periods better Both well
than previous phenylbutazo::e tolerated
therapy
Equal Present with Both study periods rated Both well
aspirin only equal to phenylbutazone tolerated
Equal Present with Both study periods rated FPN better
aspirin only equal to phenylbutazone tolerated
and indomethacin
FPN None FPN better than any Both well
better previous therapy tolerated
FPN Present with FPN better than FPN better
better aspirin only indomethacin and aspirin tolerated
Aspirin Present with Both study periods better FPN better
better aspirin only than indomethacin tolerated
Comments on the final summary form were based solely upon objective evaluation of each
patient since this was a double·blind study. The drug code has been added to these com-
ments summarised in this Table to facilita:e the comparison.




placebo, fenoprofen and aspmn being similar in this
respect.
In conclusion, fenoprofen and asplnn were similarly
effective in ameliorating the symptoms of rheumatoid
arthritis and were associated with similar effects on ob-
served laboratory values.
Assessment
Table V is a compilation of the investigator's comments
on the patients' final summary forms. The objective
assessment of each patient's progress has been tabulated.
For efficacy, aspirin was rated the better therapy in 2
patients, fenoprofen the better therapy in 4 patients, and
4 patients were rated as having equally effective therapy.
As to side-effects, 5 patients were rated as having side-
effects with aspirin only and no patients were reported to
ha ve side-effects with fenoprofen.
In the comparison of study medications with previous
therapy, all 10 patients were rated as better on the trial
than with previous therapy, which included corticosteroids,
indomethacin and phenylbutazone. Seven patients were
rated as better during both drug periods, and 3 patients
were better during fenoprofen therapy than on previous
medication. These ratings to a great extent represent the
patient input to the physician. One was impressed by the
positive effects which the frequent visits, the physician's
attention, and the whole aura of the clinical study had
upon the patients.
Vitally important, too, is the fact that in this trial q.i.d.
medication meant every 6 hours and not 4 times in the day.
These observations should be considered when comparing
the obviously superior performance of the study medi-
cations to previous therapy.
On medication dose acceptability 5 patients were rated
as tolerating both study medications equally well. Feno-
profen was rated as better tolerated in the remaining 5
patients.
CONCLUSIONS
In a limited number of patients, but with an in-depth clini-
cal trial, both fenoprofen and aspirin have been found to
be similarly effective agents in the treatment of rheu-
matoid arthritis. The equaJly beneficial effects of these
two medications have been obtained with an average daily
dose of 2,1 g fenoprofen as compared with 4,5 g aspirin.
No significant changes in the selected laboratory tests
have been observed with either study drug. Patients
reported twice as many side-effect occurrences with
aspirin as compared with fenoprofen. No drug-related
side-effects were attributed to fenoprofen therapy.
Some of the aspects of trial protocol, experimental
design and as,essment indices have been stressed.
Measurement in the rheumatic diseases remains proble-
matical and is at best based on quantifiable subjective
and objective parameters. In the face of statistical evidence
in this trial, one was perhaps most impressed by the neces-
sity to measure pain-a symptom more accurately measur-
able than at first thought." Pain is measured in terms of its
relief," and it is analgesia in rheumatolngy which the
patient ,eeks and the doctor most easily :ecognises and
records.
Trial material was supplied by Eli Lilly and Co.
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